Successful treatment of unresectable recurrent programmed death ligand 1 moderately-expressing malignant melanoma of the nasal cavity with pembrolizumab monotherapy.
Taku FujimuraYumi KambayashiYota SatoKayo TanitaHisayuki TonoChunbing LyuToshiya TakahashiAkira HashimotoSetsuya AibaPublished in: The Journal of dermatology (2019)